Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation


    Key result (from the paper’s data)
    In humans with solid tumors receiving intermittent adriamycin/cyclophosphamide, the peripheral-blood granulocytic colony-forming units (CFU-C) increased after chemotherapy: median 6 β†’ 23 CFU-C per 2Γ—108 mononuclear cells plated (p<0.001), with peaks reported up to ~20Γ— baseline around day 21. (No pluripotent stem-cell assay was available in man at the time.)



     Long Explanation


    Paper review: β€œIncrease in Circulating Stem Cells Following Chemotherapy in Man”
    Richman β€’ Weiner β€’ Yankee β€’ Blood (1976). Focus: peripheral-blood CFU-C changes after intermittent adriamycin/cyclophosphamide and feasibility of collecting autologous colony-forming cells via leukapheresis.
    Primary data source: the full text you provided (doi: 10.1182/blood.v47.6.1031.bloodjournal4761031).
    1) What was measured (and what β€œstem cells” means here)
    • Assay: peripheral-blood mononuclear cell concentrates were plated in methylcellulose with conditioned medium (CSF-containing) and colonies counted after 14 days; colonies >20 cells were scored as CFU-C.
    • Biological interpretation caveat: the authors emphasize that β€œno direct assay for pluripotential stem cells” was available in man at the time, and the circulating signal they quantify is committed granulocytic stem/progenitor activity (CFU-C), not direct HSC pluripotency.
    2) Visualize the reported group-level shift (pre vs post chemotherapy)
    Group medians are taken directly from the paper: median 6 pre-therapy (n=17) and median 23 post-therapy (n=21), with p<0.001.
    3) Visualize the reported kinetics after one course (day-by-day qualitative landmarks)
    The paper states: no CFU-C detectable at day 7, by day 15 CFU-C reaches about 5Γ— baseline, and following each course the maximum occurs around day 21 with values up to ~20Γ— baseline.
    4) Cryopreservation recovery (viability of colony-forming activity)
    • The paper reports median CFU-C recovery after thawing of 99.5% (and median total cell recovery 52%), suggesting that colony-forming capacity is largely preserved.
    • However, individual sample recovery varies widely, and values >100% are attributed to baseline quantitation difficulty when baseline CFU-C is low.
    5) Methodological strengths (what the paper did well)
    • Direct functional readout (CFU-C colony formation) rather than relying solely on peripheral differential counts; the authors report that mononuclear cell counts were not significantly changed post-therapy (p>0.3).
    • Repeated dosing kinetics concept: weekly sampling across multiple chemo courses in a patient demonstrates cyclical behavior, not just a one-off change.
    • Feasibility framing: the authors estimate leukapheresis volumes and times needed to collect a CFU-C dose β€œequivalent” to a bone marrow harvest (based on their measured CFU-C frequencies).
    6) Critical blind spots / limitations (what could mislead)
    • What exactly is β€œstem cell” here? The assay measures committed granulocytic colony-forming activity (CFU-C), not a direct measurement of pluripotent HSCs in humans; the paper acknowledges the missing direct pluripotent assay and therefore relies on analogy between primitive and committed compartments.
    • Timing heterogeneity: for some patients, the peak may occur earlier or later than day 21; the paper itself notes that in patient No. 4 the highest value was at day 14 rather than day 21. If sampling schedules are coarse, increases can be missed.
    • Small sample sizes & heterogeneity: the main group comparison uses medians from n=17 pre and n=21 post (solid tumor patients; many previously untreated females with stage III ovarian carcinoma, but not exclusively). Without randomized controls and with heterogeneity in tumor type, prior exposures, and regimen dosing, causality is limited even if the temporal association is strong.
    • Alternative explanations for increased CFU-C: mechanistic interpretations (spillover during marrow recovery, release after niche injury, removal of inhibitors, etc.) are proposed but remain unresolved within this study. The data support the association, not the mechanism.
    7) Paper takeaway (evidence-weighted)
    Claim supported by the study’s data
    • The study provides evidence that peripheral-blood CFU-C activity increases after intermittent ADR/CY chemotherapy, with a reported median post-therapy rise and time-linked peaks in a longitudinal patient.
    • CFU-C colony-forming capacity appears largely preserved by cryopreservation with median CFU-C recovery near 100% in their recovery analysis.
    Claim that is more speculative
    • The paper’s translational framing toward using peripheral-blood collected β€œstem cells” to avert myelosuppression depends on the assumption that increased CFU-C relates to the quantity of transplant-competent primitive stem cells (and/or that CFU-C measured in vitro tracks clinically relevant hematopoietic reconstitution). The authors themselves mark this as inferential since pluripotency was not directly assayed.


    Feedback:    

    Updated: March 19, 2026

     BGPT Paper Review


    Study Novelty

    90%

    Highly novel historically: it provided one of the earlier direct functional demonstrations that a chemotherapy regimen is followed by a measurable, time-resolved increase in circulating CFU-C activity and discussed feasibility of collecting autologous peripheral blood–derived clonogenic cells using leukapheresis. (Novelty is relative to the apparent pre-existing lack of such peripheral serial observations.)


    Scientific Quality

    60%

    Moderate scientific quality for its time: the CFU-C culture assay is explicit and functional; however, the study is small/nonrandomized, includes heterogeneous cancer types and treatment histories, relies on coarse timing in some cases, and the central translational inference (CFU-C β†’ clinically relevant pluripotent rescue) is necessarily inferential because a direct pluripotent assay in humans was not available.


    Study Generality

    50%

    The core observation (increased peripheral CFU-C after ADR/CY intermittent chemotherapy) is plausible but may be regimen- and context-dependent; the paper itself notes analogy may not generalize to other cytotoxic drugs and highlights unclear mechanism.


    Study Usefulness

    80%

    High historical usefulness: it motivates serial peripheral sampling and provides quantitative assay/cryopreservation feasibility data and leukapheresis order-of-magnitude calculations. Translation to clinical benefit would require further functional/engraftment endpoints beyond CFU-C frequency.


    Study Reproducibility

    60%

    Methods are relatively detailed (culture components, plating approach, CSF conditioned medium source, Ficoll-Hypaque steps, colony counting after 14 days, cryopreservation conditions including freezing rate and DMSO). However, exact replicability may be limited by missing details not visible in the provided text and by the era-specific assay context/conditioned-medium variability.


    Explanatory Depth

    50%

    Mechanisms are largely speculative and based on analogy to animal studies and general hematopoiesis recovery concepts, rather than direct mechanistic measurements in the patients.


    🎁 Authors: Collect 129 Free Science Tokens (β‰ˆ $12.9 USD)

    Claim My Author Tokens

    Use for 32 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $12.9 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    It will parse the paper’s numeric landmarks (medians, ranges, day-7/15/21 fold-changes) into arrays and generate Plotly figures for pre/post CFU-C shift and kinetics fold-changes.



     Hypothesis Graveyard


    A single-pool β€œpluripotent stem cell” mobilization model for CFU-C (i.e., that circulating CFU-C largely reflects direct appearance of pluripotent HSCs) is less favored here because the paper measures committed CFU-C and explicitly acknowledges the lack of a direct pluripotent assay in man.


    A simple explanation that CFU-C increases merely because peripheral mononuclear cell counts increase is contradicted by the paper’s reported lack of significant change in mononuclear counts pre vs post therapy.

     Science Art


    Paper Review: Increase in circulating stem cells following chemotherapy in man Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending